Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — H.C. Wainwright BioConnect Conference 2022
27 slides from Nemaura Medical's conference presentation, Jan 10, 2022
Slide 1: H.C. Wainwright BioConnect Conference
H.C. WAINWRIGHT BIOCONNECT CONFERENCE JANUARY 10 - 13, 2022, VIRTUAL CONFERENCE Dr Faz Chowdhury, CEO Nasdaq : NMRD
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms su
Slide 3: Clinical Need
Clinical Need… There are over 463 million people living with diabetes worldwide, and over $ 760 Billion was spent in the U . S . alone in 2019 for diabetes related healthcare expenditure 1 . The total addressable market exceeds $ 150 Billion 2 , 3 , 4 . Obesity and Diabetes are two of the major driv
Slide 4: Why CGM? BGM Misses the full picture!
Why CGM? BGM Misses the full picture!
Slide 5: Nemaura's Vision
Nemaura’s Vision Lead in the Prevention, Management, & Reversal of Type 2 Diabetes using a low - cost, flexible, user - friendly device and digital ecosystem.
Slide 6: Our Approach
Our Approach ▪ Skin mounted (disposable) sensor & (non - disposable) transmitter. Glucose extracted to the surface of the skin ▪ Sensors use well established glucose oxidase enzyme to convert glucose to an electric current signal ▪ Low energy bluetooth sends this to the phone app every 5 minutes whe
Slide 7: Product Positioning
Product Positioning sugarBEAT® CGM – Direct sales to consumers that wish to purchase sensors to measure glucose profiles on days they choose. www.sugarBEAT.com BEAT®diabetes Program: a subscription - based diabetes management program. Currently in pilot and plan is to sell to employers and insurers.
Slide 8: sugarBEAT Regulatory Status
sugarBEAT ® Regulatory Status ▪ CE Approved Class 2b Medical Device in Europe ▪ FDA PMA submitted and review still in progress: • BIMO Audit conducted in December 2021 at Nemaura’s UK facility. A single 483 observation was issued. Company has committed to a full and complete response this quarter. •
Slide 9: sugarBEAT Sales Status UK
sugarBEAT ® Sales status UK ▪ UK: 200,000 sensors ordered by licensee following soft launch success ▪ Delivered first batch of transmitter devices in December 2021, with rolling bi - weekly/monthly delivery planned. ▪ Purchase order forecast for (approximately) a further 100,000 per month for the ne
Slide 10: sugarBEAT Sales Status - Outside UK
sugarBEAT ® Sales Status - Outside - UK Planning direct to consumer launch of sugarBEAT outside of UK where CE approval is accepted, such as Europe and Middle East.
Slide 11: sugarBEAT How it works
sugarBEAT” rning, : ; 9 ecamanename How it works J You in your target ronge © clucore lve ) Time I E 09:03 @ id ee See changes as they happen Helps you understand your unique glucose trend line and lifestyle choices taken.
Slide 12: sugarBEAT Testimonials
sugarBEAT ® Testimonials* MySugarWatch offered me a needle - free blood glucose monitoring solution that’s non - invasive and easy to use. I didn’t even realize I had the My Sugar watch device on my arm as it is so lightweight. It gives me the assurance that my blood sugar reading is accurate, and I
Slide 13: sugarBEAT Testimonials: Volunteer data vs BGM and invasive CGM
sugarBEAT ® Testimonials Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM sugarBEAT® Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)
Slide 14: Type 2 Diabetes prevention and management program launched in the U.S.
Type 2 Diabetes prevention and management program launched in the U.S.
Slide 15: BEATdiabetes – Components
BEAT ® diabetes – 3 Components ▪ Weight loss program originally developed at the Joslin Diabetes Centre – over 12 years of clinical evidence (based on an in - clinic program, subsequently replicated using a virtual program). Sustained long term weight loss achieved without loss of muscle mass ▪ proB
Slide 16: Miboko 'Mind Body Connect'
Miboko ‘MIND BODY CONNECT’ A metabolic health program comprising an app and integrated glucose sensor
Slide 17: Miboko: A Mass-Market Consumer Product
Miboko : A Mass - Market Consumer Product Download the app and on - board Sensor measures metabolic health score Receive report and weekly targets Applicable to over 80 million people in the U.S. with prediabetes as well as general health - conscious individuals, and obesity market.
Slide 18: Miboko: Key Competition
Miboko : Key Competition Noom: Over 50 million subscribers, >$400m revenues in 2020 5 Miboko USP: A holistic metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight into what’s really happening inside the body
Slide 19: Miboko: Launch Update
Miboko : Launch Update Marketing activities thus far: restricted mainly to low - key organic social media campaign. Over 5000 registrations during the last few weeks of BETA launch, with more than 60% conversion for on - boarding Large scale marketing campaign planned for 2022
Slide 20: Miboko: Key Competition
Miboko : Key Competition What about other competition with programs using invasive 10 - 14 day CGM? Invasive CGM’s require a prescription in the U.S. Skin trauma from needle and/or adhesive Reports of pain when pulling sensor filament out of arm These factors may make invasive sensors challenging fo
Slide 21: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 22: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits . Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Globa
Slide 23: The Team
The Team ▪ We are building a world class team ▪ So far includes senior level appointments, with experience from companies including: Dexcom, Lifescan , Abbvie , & Eli Lilly ▪ Hiring for Chief Marketing and Sales Officers – U.S. and EU
Slide 24: The Team – Most recent addition
The Team – Most recent addition Chief Operating Officer, COO Dr Arash Ghadar : Over 20 years as technical and operational experience, last 10 years as COO of an electronics development and manufacturing c ompany. Dr Ghadar obtained a PhD in Bio - sensors from Warwick University and holds a Bachelors
Slide 25: Intellectual Property
Intellectual Property ▪ IP consists of several filed p atents and substantial know - how ▪ Two key sensor - related patents are not yet published, relating to novel device and composition
Slide 26: Summary
Summary ▪ CE Class 2b Medical Device Approval – and subsequent user testimonials and order for 200,000 sensors (from UK Licensee) and first batch delivery made in D ecember 2021. ▪ FDA PMA review is in progress; audits in relation to PMA, conducted and in - progress ▪ Simple revenue generation model
Slide 27: References
References 1. https://www.idf.org/aboutdiabetes/what - is - diabetes/facts - figures.html 2. https://drug - dev.com/global - type - 2 - diabetes - market - set - to - almost - double - to - 58 - 7 - billion/ 3. https ://www.prnewswire.com/news - releases/global - digital - diabetes - market - outloo
Nemaura Medical — H.C. Wainwright BioConnect Conference 2022 on 6ix